SUNPHARMA.NS Profit & Loss
Sun Pharmaceutical Industries Ltd.
Profit & Loss Balance Sheet Cash Flow
Profit & Loss · 4 years on file
(FY2022-23 to FY2025-26)
· fetched 2026-08-24 01:42
| Line item | FY2022-23 | FY2023-24 | FY2024-25 | FY2025-26 | Source (XBRL element) |
|---|---|---|---|---|---|
| Revenue from Operations | ₹438.86 Bn | ₹484.97 Bn | ₹525.78 Bn | ₹584.62 Bn | RevenueFromOperations |
| Gross Revenue (incl. inter-segment) | N/A | N/A | N/A | N/A | SegmentRevenueFromOperations |
| Other Income | ₹6.35 Bn | ₹13.54 Bn | ₹19.65 Bn | ₹19.72 Bn | OtherIncome |
| Total Income | ₹445.20 Bn | ₹498.51 Bn | ₹545.43 Bn | ₹604.34 Bn | Income |
| Cost of Materials Consumed | ₹77.78 Bn | ₹69.04 Bn | ₹64.49 Bn | ₹73.89 Bn | CostOfMaterialsConsumed |
| Purchases of Stock-in-Trade | ₹35.72 Bn | ₹34.66 Bn | ₹41.48 Bn | ₹38.12 Bn | PurchasesOfStockInTrade |
| Changes in Inventories | ₹-6.87 Bn | ₹2.92 Bn | ₹1.50 Bn | ₹3.43 Bn | ChangesInInventoriesOfFinishedGoodsWorkInProgressAndStockInTrade |
| Employee Benefit Expense | ₹82.96 Bn | ₹94.29 Bn | ₹99.73 Bn | ₹114.19 Bn | EmployeeBenefitExpense |
| Finance Costs | ₹1.72 Bn | ₹2.38 Bn | ₹2.31 Bn | ₹3.39 Bn | FinanceCosts |
| Depreciation and Amortisation | ₹25.29 Bn | ₹25.57 Bn | ₹25.75 Bn | ₹29.38 Bn | DepreciationDepletionAndAmortisationExpense |
| Other Expenses | ₹132.81 Bn | ₹153.82 Bn | ₹165.86 Bn | ₹177.68 Bn | OtherExpenses |
| Total Expenses | ₹349.40 Bn | ₹382.69 Bn | ₹401.13 Bn | ₹440.07 Bn | Expenses |
| Profit Before Exceptional Items and Tax | ₹95.80 Bn | ₹115.82 Bn | ₹144.30 Bn | ₹164.26 Bn | ProfitBeforeExceptionalItemsAndTax |
| Exceptional Items | ₹-1.71 Bn | ₹-4.94 Bn | ₹-6.78 Bn | ₹-13.07 Bn | ExceptionalItemsBeforeTax |
| Profit Before Tax | ₹94.08 Bn | ₹110.88 Bn | ₹137.52 Bn | ₹151.19 Bn | ProfitBeforeTax |
| Tax Expense | ₹8.48 Bn | ₹14.39 Bn | ₹27.72 Bn | ₹35.54 Bn | TaxExpense |
| Net Profit (incl. minority interest) | ₹85.13 Bn | ₹96.10 Bn | ₹109.65 Bn | ₹115.09 Bn | ProfitLossForPeriod |
| Net Profit (to shareholders) | ₹84.74 Bn | ₹95.76 Bn | ₹109.29 Bn | ₹114.79 Bn | ProfitOrLossAttributableToOwnersOfParent |
| Basic EPS | ₹35.30 | ₹39.90 | ₹45.60 | ₹47.80 | BasicEarningsLossPerShareFromContinuingAndDiscontinuedOperations |
| Diluted EPS | ₹35.30 | ₹39.90 | ₹45.60 | ₹47.80 | DilutedEarningsLossPerShareFromContinuingAndDiscontinuedOperations |
Every figure above is the exact value of the named XBRL element from SUNPHARMA.NS's cached filing for that year — nothing here is estimated or backfilled. A company shows one column per year StockProof actually has data for — never padded with blank years. Rows shown as N/A are genuinely not disclosed under that year's filing format (see peer comparison for how other Healthcare companies compare).